Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abrilumab
- Development stage
- Phase 2
- Lead developer
- MedImmune
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Abrilumab is a fully human monoclonal IgG2 antibody that targets the α4β7 integrin heterodimer. By binding with high affinity to α4β7 integrin, it blocks its interaction with mucosal addressin cell adhesion molecule-1 (MAdCAM-1), which is selectively expressed in gut endothelium and upregulated in patients with inflammatory bowel disease (IBD). This blockade inhibits the migration of leukocytes into gastrointestinal tissue, thereby reducing inflammation associated with conditions such as ulcerative colitis and Crohn's disease. Abrilumab was developed for the treatment of inflammatory bowel diseases but has not been approved for any indication[1][3][5][6].
- Brand names
- abrilumab
- Other names
- Anti-α4β7 integrin monoclonal antibodyabrilimumab
02
Targets
α4β7 (Integrin alpha-4 beta-7 heterodimer)
Beyond the preview
Go deeper on abrilumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abrilumab.